Education
About Us
Working with TipRanks
Follow Us
SpectraCure AB (SE:SPEC)
:SPEC
Top Page
SpectraCure AB
(Frankfurt:SPEC)
28Underperform
SpectraCure AB (SPEC) vs. S&P 500 (SPY)
Market Cap
kr77.41M
Dividend YieldN/A
Average Volume (3M)159.07K
Price to Earnings (P/E)―
Beta (1Y)-0.88
Revenue GrowthN/A
EPS Growth-13.59%
CountrySE
Employees13
SectorHealthcare
Sector Strength53
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.24
Shares Outstanding97,131,610
10 Day Avg. Volume358,386
30 Day Avg. Volume159,075
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
SpectraCure AB Business Overview & Revenue Model
Company DescriptionSpectraCure AB (SPEC) is a medical technology company focused on developing innovative cancer treatment solutions. The company specializes in photodynamic therapy (PDT), a minimally invasive treatment method that uses laser technology to activate a photosensitive drug for the effective targeting and destruction of cancer cells. SpectraCure primarily targets hard-to-treat cancers, such as prostate cancer, with its proprietary Interstitial Photodynamic Therapy (IPDT) system designed to improve patient outcomes and reduce side effects associated with traditional cancer treatments.
How the Company Makes MoneySpectraCure AB generates revenue through the commercialization of its Interstitial Photodynamic Therapy (IPDT) system. The company sells its IPDT equipment and related consumables to hospitals, clinics, and cancer treatment centers. Additionally, SpectraCure may engage in strategic partnerships and collaborations with medical institutions and research organizations to further develop and expand the application of its technology. Licensing agreements and service contracts for maintenance and training related to the use of its PDT systems also contribute to its income. The company may also receive funding through grants and investments aimed at advancing cancer treatment technologies.
SpectraCure AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 318.00K | 539.00K | 0.00 | 1.21K | 763.00 | Gross Profit |
| -9.22M | 3.58M | 1.39M | 2.35M | 2.62M | EBIT |
| -21.35M | -26.98M | -24.42M | -16.46M | -14.29M | EBITDA |
| -20.97M | -22.27M | -20.43M | -12.88M | -11.35M | Net Income Common Stockholders |
| -20.44M | -25.33M | -23.34M | -15.41M | -13.69M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 56.95M | 93.18M | 129.69M | 157.24M | 54.21M | Total Assets |
| 144.83M | 162.42M | 190.52M | 210.53M | 100.19M | Total Debt |
| 6.72M | 2.70M | 4.90M | 5.36M | 6.71M | Net Debt |
| -50.23M | -90.48M | -124.79M | -151.88M | -47.49M | Total Liabilities |
| 14.97M | 12.12M | 14.84M | 13.32M | 12.41M | Stockholders Equity |
| 129.86M | 150.30M | 175.68M | 197.22M | 87.78M |
| Cash Flow | Free Cash Flow | |||
| -34.45M | -33.08M | -27.09M | -19.99M | -25.18M | Operating Cash Flow |
| -18.68M | -22.96M | -18.60M | -9.40M | -10.05M | Investing Cash Flow |
| -15.56M | -11.35M | -8.49M | -10.58M | -15.13M | Financing Cash Flow |
| -1.99M | -2.20M | -453.00K | 123.02M | 34.32M |
SpectraCure AB Technical Analysis
Negative
0.77
Price Trends
1.76
Negative
2.17
Negative
2.08
Negative
Market Momentum
-0.22
Positive
18.68
Positive
9.18
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPEC, the sentiment is Negative. The current price of 0.77 is below the 20-day moving average (MA) of 1.58, below the 50-day MA of 1.76, and below the 200-day MA of 2.08, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 18.68 is Positive, neither overbought nor oversold. The STOCH value of 9.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SPEC.
SpectraCure AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.23B | 3.70 | -41.86% | 2.84% | 16.58% | -0.16% | |
46 Neutral | kr207.86M | ― | -102.63% | ― | -0.61% | 54.19% | |
43 Neutral | kr130.24M | ― | -151.03% | ― | 27.78% | 43.32% | |
37 Underperform | kr166.80M | ― | -159.24% | ― | -22.50% | 76.74% | |
34 Underperform | kr67.74M | ― | ― | ― | ― | ||
34 Underperform | kr60.50M | ― | -82.35% | ― | 127.04% | 92.31% | |
28 Underperform | kr77.41M | ― | -19.16% | ― | ― | -13.59% |
* Healthcare Sector Average
Performance Comparison
SE:SPEC
SpectraCure AB
0.77
-2.22
-74.25%
SE:ACARIX
Acarix AB
0.20
-0.10
-34.56%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
3.00
-11.79
-79.71%
SE:QLINEA
Q-linea AB
0.04
-0.29
-88.72%
SE:SCIB
SciBase Holding AB
0.39
0.07
20.00%
SE:HEART
Scandinavian Real Heart AB
15.40
-14.68
-48.81%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.